[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aphasia-primary-progressive\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aphasia-primary-progressive":92},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100472843","investigating-speech-sequencing-in-neurotypical-speakers-and-persons-with-disordered-speech-100472843",false,"NCT05437159","Investigating Speech Sequencing in Neurotypical Speakers and Persons With Disordered Speech","Sequencing and Initiation in Speech Production: Investigating Speech Sequencing in Neurotypical Speakers, Persons Who Stutter, and Persons With Primary Progressive Aphasia","Inclusion Criteria\n\n* Healthy individuals with no history of neurological, speech, or hearing disorders (other than stuttering in studies that involve adults who stutter).\n* To maximize the uniformity of prior exposure to the speech stimuli that will be used, only native speakers of American English will be recruited, and only those with limited exposure to a second language will be enrolled.\n* All adult participants will also pass a standard pure-tone hearing screening at a 25dB hearing level threshold at 500, 1k, 2k, and 4kHz frequencies.\n* All participating children will pass a hearing screening at a 20 dB threshold at 500, 1k, 2k, and 4k Hz.\n* Participants in experiments that require them to read orthographic stimuli must have normal or corrected-to-normal vision (MRI-safe corrective glasses are available at the Boston University Cognitive Neuroimaging Center for use during neuroimaging).\n* Participating children will complete additional speech, language, hearing, and cognitive tests to ensure that they are within normal performance ranges for their age with the exception of stuttering for children in the children who stutter (CWS) group.\n* Persons who stutter will be evaluated formally by a speech-language pathologist to assess stuttering severity and to ensure the absence of other speech or language disorders. PWS will have no history of neurological disorder other than stuttering, and will demonstrate very mild to severe stuttering according to the Stuttering Severity Instrument for Children and Adults - 4th Edition (SSI-4: PRO-ED, Inc.), that is confirmed by clinical reports and expressed concern by the subject and\u002For guardian.\n* Participants with primary progressive aphasia (PPA) will have been diagnosed through the Massachusetts General Hospital Frontotemporal Disorders Unit (MGH-FTD) by an experienced neurologist in coordination with a speech-language pathologist.\n* Participants with PPA will have a score of 1.0 or lower on the Clinical Dementia Rating scale (i.e., mild cognitive impairment or mild dementia) to ensure cognitive levels are sufficient to complete the task.\n* All participants with PPA must have a recent clinical assessment and T1 structural neuroimaging scan through the MGH-FTD Unit for eligibility for this study.\n\nExclusion Criteria\n\n* Participants in studies that involve tDCS or MRI scanning will have no contraindications specific to those procedures. For the tDCS study, this includes individuals who have a metallic implant in the head or electrically sensitive devices implanted in the body, a history of seizures, significant scalp lesions, or pregnancy.\n* For MRI studies, this includes a history of seizures, severe claustrophobia, the presence of magnetically or mechanically active implant, ferromagnetic material embedded in any part of the body, or pregnancy).\n* All participants will perform a standardized nonword repetition pre-test (the Dollaghan and Campbell Nonword Repetition Task) to assess working memory performance. Participants who perform more than 2 standard deviations below the norm for their age range will be deemed to be unable to perform the experimental task and released from further participation.\n* Participating children will have no history of neurological disorder other than stuttering, and will demonstrate very mild to severe stuttering according to the Stuttering Severity Instrument for Children and Adults, 4th Edition, that is confirmed by clinical reports and expressed concern by the subject and\u002For guardian.\n* Children under the age of 6 and over the age of 8 will not enrolled in this study.\n* Participants with PPA will not be eligible for this study if they are taking any medications that would be expected to affect speech or language.",true,"ALL","6 Years",{"count":20,"type":21},2,"ESTIMATED","INTERVENTIONAL",[24],"NA","Persistent developmental stuttering affects more than three million people in the United States, and it can have profound adverse effects on quality of life. Despite its prevalence and negative impact, stuttering has resisted explanation and effective treatment, due in large part to a poor understanding of the neural processing impairments underlying the disorder. The overall goal of this study is to improve understanding of the brain mechanisms involved in speech motor planning and how these are disrupted in neurogenic speech disorders, like stuttering. The investigators will do this through an integrated combination of experiments that involve speech production, functional MRI, and non-invasive brain stimulation. The study is designed to test hypotheses regarding the brain processes involved in learning and initiating new speech sound sequences and how those processes compare in persons with persistent developmental stuttering and those with typical speech development. These processes will be studied in both adults and children. Additionally, these processes will be investigated in patients with neurodegenerative speech disorders (primary progressive aphasia) to further inform the investigators understanding of the neural mechanisms that support speech motor sequence learning. Together these experiments will result in an improved account of the brain mechanisms underlying speech production in fluent speakers and individuals who stutter, thereby paving the way for the development of new therapies and technologies for addressing this disorder.",[27,28],"Stuttering, Developmental","Aphasia, Primary Progressive",[27,30,31,32,33,34],"Magnetic Resonance Imaging","Transcranial Direct Current Stimulation","Speech Motor Learning","Speech Disorders","Neurocomputational Modeling","RECRUITING","2026-04-28",{"date":38,"type":39},"2026-05-04","ACTUAL",{"date":41,"type":39},"2023-04-03",{"date":43,"type":21},"2026-05",{"name":45,"class":46},"Boston University Charles River Campus","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100521216","early-phase-1-propranolol-in-primary-progressive-aphasia-100521216","NCT06066710","Propranolol in Primary Progressive Aphasia","Trial of Propranolol in Older Adults with Primary Progressive Aphasia","Inclusion Criteria:\n\n* 1\\. Age: 50 and older\n* 2\\. Primary Progressive Aphasia diagnosis\n* 3\\. Native English speaker\n\nExclusion Criteria:\n\n* 1\\. Unable to provide consent\n* 2\\. Taking alpha 2 agonists (clonidine and guanfacine)\n* 3\\. Other major psychological or neurological diagnosis\n* 4\\. Major head trauma that contributed to their condition\n* 5\\. Allergic reaction to adhesives\n* 6\\. Uncorrected vision\u002Fhearing impairments\n* 7\\. Diabetes\n* 8\\. Reactive airway disease\n* 9\\. Untreated hypothyroidism\n* 10\\. Bradyarrhythmia\n* 11\\. Unexplained syncope\n* 12\\. Pregnancy (assessed verbally on the days of MR imaging)\n* 13\\. Drugs that interact with propranolol, such as alpha 2 agonists\n* 14\\. Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning. Subjects with any implanted device that cannot be verified as MRI compliant will be excluded.","50 Years",{"count":56,"type":21},30,[58],"EARLY_PHASE1","The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressive Aphasia. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure.\n\nThis research is being done because there are currently no drug treatment options for language impairments and anxiety often experienced by people with Primary Progressive Aphasia.",[28],"2025-03-24",{"date":63,"type":39},"2025-03-28",{"date":65,"type":39},"2025-01-13",{"date":67,"type":21},"2027-12",{"name":69,"class":46},"University of Missouri-Columbia",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":88,"leadSponsor":90,"locationsCount":70},"100552486","effects-of-transcranial-direct-current-stimulation-tdcs-on-inhibition-and-brain-function-in-primary-progressive-aphasia-100552486","NCT06473714","Effects of Transcranial Direct Current Stimulation (tDCS) on Inhibition and Brain Function in Primary Progressive Aphasia","Stim-APHA","Inclusion Criteria:\n\n* Be a male or female over the age of 18 with a primary progressive aphasia diagnosis\n* Available for treatment and testing sessions\n* able to read and speak French\n* Be right-handed\n\nExclusion Criteria:\n\n* Presence of neurodevelopmental disorders or non-degenerative neurological disorders\n* Post-stroke aphasia\n* Language or cognitive disorders too severe to allow task performance or communication\n* Pre-existing psychiatric disorders; severe depression, schizophrenia\n* People with pacemakers or metal implants, epilepsy\n* Presence of a medical condition that represents a contraindication to tDCS\n* Active use of psychotropic drugs\n* Treatment with tDCS or TMS in the last 3 months\n* Additional language therapy\n* Pregnancy or breast-feeding","18 Years",{"count":80,"type":21},20,[24],"Primary progressive aphasia (PPA) is a focal dementia characterized by primary impairment of language abilities and functional disturbances associated with language.\n\nAlthough PPA is a progressive disorder, new techniques are being proposed to try to activate parts of the brain previously thought to be potentially inactive, due to the possibility of \"neuroplasticity\". This concept refers to our brain's modularity and learning potential. Transcranial direct current stimulation is a powerful neuromodulatory technique, in which a small current is applied to the participant's scalp through the targeted positioning of an anode and a cathode. The positive or anodal stimulation of tDCS is supposed to increase neuronal activity under the electrode, while cathodal stimulation is supposed to do the opposite.\n\nThis project will provide new insights into the nature of the neural activity underlying executive functions in people with primary progressive aphasia compared to those without. The investigators expect to find reduced amplitude of electrophysiological responses and lower accuracy in people with primary progressive aphasia compared with healthy controls. Given the results of previous studies showing the efficacy of tDCS protocols in the treatment of aphasia, the investigators might expect them to improve executive functions. If so, the investigators expect significantly greater electrophysiological responses after stimulation sessions compared with sham conditions. This project is of great clinical relevance. This research will improve current therapeutic protocols used in the treatment of PPA by providing critical findings on whether and how the use of tDCS improves executive functions. Crucially, the research will advance knowledge of executive function decline as a sensitive marker of PPA, informing us about the possibility of early detection of this disorder. At the same time, the investigators will analyze the possibility of controlling symptomatological evolution via the analysis of acoustic and vocal markers. This will enable us to observe the evolution of sensory markers such as acoustic markers according to symptomatological evolution. This will enable us to check whether acoustic markers correlate with the patient's level of symptomatological impairment and\u002For pathological physiological data.",[28],"2024-11-04",{"date":86,"type":39},"2024-11-05",{"date":84,"type":39},{"date":89,"type":21},"2027-09",{"name":91,"class":46},"Centre Hospitalier Universitaire de Nice","Aphasia Primary Progressive"]